GINKGO BIOWORKS HOLDINGS, INC. (DNA) Operating Margin
- Operating margin · 12 months: Value -231.13%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -231.13% | Operating income / revenue. Period ending 2026-06-30. $-306.06M ÷ $132.42M × 100 ≈ -231.13% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -306.06M USD | Operating Income (Loss) |
| Revenue | 132.42M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 215.61M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-306.06M | $132.42M | (m) | $215.61M | (m) | -231.13% |
| 2026-03-31 | $-305.68M | $151.40M | (m) | $222.77M | (m) | -201.90% |
| 2025-12-31 | $-315.28M | $170.16M | (m) | $243.77M | (m) | -185.29% |
| 2025-09-30 | $-348.13M | $180.61M | (m) | $270.02M | (m) | -192.76% |
| 2025-06-30 | $-313.32M | $230.81M | (m) | $277.68M | (m) | -135.74% |
| 2025-03-31 | $-470.72M | $237.42M | (m) | $358.53M | (m) | -198.27% |
| 2024-12-31 | $-559.76M | $227.04M | (m) | $424.06M | (m) | -246.54% |
| 2024-09-30 | $-634.27M | $217.95M | (m) | $464.72M | (m) | -291.01% |
| 2024-06-30 | $-865.46M | $184.34M | (m) | $544.38M | (m) | -469.50% |
| 2024-03-31 | $-826.66M | $208.70M | (m) | $554.44M | (m) | -396.11% |
| 2023-12-31 | $-864.41M | $251.46M | (m) | $580.62M | (m) | -343.76% |
| 2023-09-30 | $-917.15M | $314.99M | (m) | $641.13M | (m) | -291.17% |
| 2023-06-30 | $-1.29B | $325.95M | (m) | $745.93M | (m) | -394.44% |
| 2023-03-31 | $-1.75B | $390.00M | (m) | $891.71M | (m) | -448.54% |
| 2022-12-31 | $-2.21B | $477.71M | (m) | $1.05B | (m) | -462.41% |
| 2022-09-30 | $-3.66B | $527.91M | (m) | $1.86B | (m) | -693.14% |
| 2022-06-30 | $-3.03B | $539.13M | (m) | $1.65B | (m) | -562.54% |
| 2022-03-31 | $-2.45B | $438.14M | (m) | $1.41B | (m) | -558.23% |
| 2021-12-31 | $-1.83B | $313.84M | (m) | $1.15B | (m) | -582.62% |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-137.03M | $76.66M | (m) | $159.77M | (m) | -178.75% |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-71.60M | $54.18M | (m) | $96.30M | (m) | -132.14% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.